A REVIEW ON NANOPARTICLE CROSS-LINKED COLLAGEN SHIELD FOR SUSTAINED DELIVERY OF DRUG IN GLAUCOMA

Glaucoma is a disease of the optic nerve. Progressive damage of the optic nerve will causes irreversible reduction in visual acuity; it leads to visual field loss and blindness. The main treatment of glaucoma is the reduction of intraocular pressure. Current therapy involves frequent administration of eye drops which results in poor patient adherence and therapeutic outcomes. This review is focusing on to overcome these limitation by developing a novel nanoparticle cross-linked collagen shield for sustained delivery of suitable drug. The drug is incorporate into the shield and cross-linked by cross-linking agent with the help of Ultraviolet irradiation. Metal oxide nanoparticles is most suitable as cross-linking agent.e.g-polyvinylpyrrolidone (PVP) capped zinc oxide (ZnO/PVP).There is some evaluation parameter for nanoparticle cross-linked collagen shield like cytotoxicity as well as shield transparency. Cross-linked collagen shields characterise for their mechanical strength, swelling capacity and bioadhesive properties, ZnO/PVP NP cross-linked shields is the most favourable characteristics compare to plain film. It release drug over a period of 14 days offering a promising sustained release treatment option for glaucoma. The purpose of this review article is to provide information about novel Nanoparticle cross-linked collagen shield for sustained delivery of drug.